BIFOSFONATOS EN ODONTOLOGIA PDF

Background: The use of osteoclast inhibitors in metastatic bone disease, increase bone mineral density and reduce the risk of fracture, patients with osteonecrosis have been reported after the chronic use of these inhibitors. In our country, the use of osteoclast inhibitors is in the context of osteoporosis and bone metastases, so it is important to describe the incidence of this complication in Mexican population. We included all patients who received bisphosphonates or denosumab in the context of metastatic bone disease due to solid tumors and who had osteonecrosis of the jaw. Results: A patients who used bisphosphonates or denosumab in metastatic bone disease bisphosphonates and denosumab. Of these, 28 3.

Author:Megis Mujin
Country:Serbia
Language:English (Spanish)
Genre:Relationship
Published (Last):28 September 2004
Pages:335
PDF File Size:8.75 Mb
ePub File Size:19.15 Mb
ISBN:432-3-60412-374-9
Downloads:88636
Price:Free* [*Free Regsitration Required]
Uploader:Arazilkree



Sociedad de Periodoncia de Chile. Sociedad de Ortodoncia de Chile. Scielo , ScienceDirect, Latindex, Redalyc. Los resultados indican, que los pacientes en mayor riesgo de desarrollar osteonecrosis de los maxilares son aquellos que reciben terapia con bifosfonatos nitrogenados intravenosos.

El manejo de las lesiones es de alta complejidad. In recent years, due to different causes, an increasing number of patients are under medical treatment with bisphosphonates.

These drugs might be associated with the growing of spontaneous ulceration of the oral mucosa and osteonecrosis of the jaws. The purpose of this review is to describe the characteristics of bisphosphonates, its mechanism of action, clinical manifestation of osteonecrosis of the jaws, therapeutic management and prevention.

Patients treated with intravenous nitrogen-containing bisphosphonates, have a major risk to develop osteonecrosis. The mandible is more commonly affected than the maxilla. Probably the origin of the osteonecrosis of the jaws is a decreased microcirculation and a limited bone turnover due to bisphosphonates, leading to diminish their healing capacity and regeneration of the tissues.

The management of the lesions is difficult. Palliative treatment is proposed with oral rinses and systemic antibiotic therapy. Removal of necrotic bone is recommended in severe cases. In conclusion, is necessary to know this condition for an early diagnosis and treatment, so to prevent its apparition. In this way, it is recommendable to do an oral examination and diagnosis, to treat active oral infections and eliminate sites at high risk for infection before getting the bisphosphonate therapy started.

Furthermore, to avoid surgical procedures in risky patients. Key words: Key words: osteonecrosis, bisphosphonates, osteonecrosis of the jaws. Abstract In recent years, due to different causes, an increasing number of patients are under medical treatment with bisphosphonates.

Rheumathology: 15 Ostoporosis. CMAJ, , pp. The use of bisphosphonates in elderly cancer patients. Oncologist, 12 , pp. A review of Bisphosphonate-associated osteonecrosis of the jaws and its management. JCDA, 73 , pp. Medical management update: Multiple myeloma. Pamidronate Aredia and Zolendronate Zometa induced avascular necrosis of the jaws: a growing epidemic.

J Oral Maxillofac Surg, 61 , pp. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol, 21 , pp. Osteonecrosis of the jaws associated with the use of Bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg, 62 , pp.

Avascular jaw Osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med, 34 , pp. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of the 11 cases. Int J Oral Maxillofac Surg, 35 , pp. Quim Nova, 28 , pp. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone reorption by preventing protein prenylation: evidence from structure-activity relationships in J macrophages.

J Bone Miner Res, 13 , pp. Gutta Rajesh,Louis Patrick. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Joan Otomo-Corgel. Implants and oral bisphosphonates: risky business? J Periodontol, 78 , pp.

J Oral Maxillofac Surg, 63 , pp. Pini Prato. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol, 32 , pp. Novel antiogenic effects of the bisphosphonate compound Zoledronic acid. JPET, , pp.

Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol en prensa. Fleisch Herbert. Bisphosphonates: Mechanisms of action. Endocrine Reviews, 19 , pp. Effect of long—term oral bisphosphonates on implant wound healing: literature review and a case report.

Nitrogen-containing bisphosphonates inhibit the Mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Osteonecrosis associated with the use of biphosphonates: Case report. Rev Med Chile, , pp. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc, , pp. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia.

J Oral Maxillofac Surg, 65 , pp. Bisphosphonate-associated osteonecrosis of the jaws Report of a case and literature review. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.

Oral and intravenous bisphosphonates induced osteonecrosis of the jaws History, etiology, prevention and treatment. Quintessence Publishing Co Inc, , pp. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, , pp. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 23 , pp. Osteonecrosis of the jaws: maxillofacial recommendations for bisphosphonate prescribers.

J Intern Med, , pp. Margarone 3rd,J. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. Osteonecrosis of the jaws and bisphosphonates Report of three cases. Int J Oral Maxillofac Implants, 22 , pp.

Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol, 77 , pp.

Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis. Int J Periodontics Restorative Dent, 26 , pp. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants, 21 , pp.

Orthodontic treatment of patients using bisphosphonates: A report of 2 cases. Am J Orthod Dentofacial Orthop, , pp. Bourgeois Jr. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod, 31 , pp. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases.

N Eng J Med, , pp. Posible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab, 92 , pp. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a month, randomized, placebocontrolled study.

J Periodontol, 76 , pp. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. J Orthop Sci, 12 , pp. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials, 26 , pp.

KENNETH HIGBEE YOUR MEMORY PDF

Osteonecrosis de los Maxilares Asociado a Terapia con Bifosfonatos: Situación Actual

Sociedad de Periodoncia de Chile. Sociedad de Ortodoncia de Chile. Scielo , ScienceDirect, Latindex, Redalyc. Los resultados indican, que los pacientes en mayor riesgo de desarrollar osteonecrosis de los maxilares son aquellos que reciben terapia con bifosfonatos nitrogenados intravenosos.

LEAFLET GL24 PDF

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy. See our Privacy Policy and User Agreement for details. Published on Sep 4,

HEGEL NAUKA LOGIKI PDF

Bisphosphonate induced osteonecrosis of the jaws: prevention and therapeutic approach. Barrientos Lezcano 1 , B. Peral Cagigal 1 , G. Serrat Soto 2 , A.

Related Articles